Clinical Trial Update: Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating weekly Idrabiotaparinux sodium versus adjusted-dose warfarin in atrial fibrillation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Idrabiotaparinux sodium (idrabiotaparinux sodium)
• Warfarin (warfarin)

Snippet

Sponsor: Sanofi | Conditions: Atrial Fibrillation | Phase 3 | Status: TERMINATED